natgillin/translations-raw huggingface dataset:
The pharmaceutical composition of claim 10, wherein the HCV antiviral agent is an antiviral selected from the group consisting of a HCV protease inhibitor and a HCV NS5B polymerase inhibitor. 
Farmaceutska kompozicija prema patentnom zahtjevu 11, naznačena time što je HCV antivirusno sredstvo - antivirusno sredstvo izabrano iz grupe koju čine inhibitor HCV proteaze i inhibitor HCV NSSB polimeraze.
wherein R′ and R″, the same or different, represent a hydrogen atom, or they are selected from linear or branched C1-C20 alkyl groups, cycloalkyl groups optionally substituted; aryl groups optionally substituted; 
1 R", isti ili različiti, predstavljaju atom vodika, ili su izabrani od linearnih ili granatih C;-C2o alkil grupa, cikloalkil grupa izborno supstituiranih; aril grupa izborno supstituiranih;
or a pharmaceutically acceptable salt or hydrate thereof; wherein the virus is selected from the group consisting of viruses of the orthomyxoviridae, paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae, and coronaviridae families. 
[image] naznačen time da A je NH2; i B je H; ili njegova farmaceutski prihvatljiva sol ili hidrat, za primjenu u inhibiciji virusne RNK polimeraze izabrane iz grupe koja se sastoji od virusnih polimeraza orthmyxoviridae, paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae i coronaviridae.
An expanded polystyrene molded article (I) wherein the expanded polystyrene molded article is prepared by expansion molding the expanded polystyrene particle provided with a skin layer according to claim 1 by steam-heating; or 
artikl oblikovan od ekspandiranog polistirena se načini oblikovanjem ekspandiranjem čestice ekspandiranog polistirena, koja dobiva površinski sloj u skladu s patentnim zahtjevom 1 grijanjem vodenom parom; ili
The method according to claim 4, wherein the crystallization solvent is preferably a mixed solvent of ethanol/water. 
Postupak sukladno zahtjevu 5, naznačen time što je otapalo za kristalizaciju poželjno mijeešano otapalo etanol / voda.
LC/MS=high performance liquid chromatography/mass spectrometry MS or Mass Spec=mass spectrometry 
= tekuća kromatografija visoke performanse /spektrometrija mase MS ili Mass Spec = spektrometrija mase
A method of producing the refrigerant composition according to claim 1 comprising mixing 36 to 50 mass% of 1,1,1,2-tetrafluoroethane (HFC134a) with 50 to 64 mass% of 2,3,3,3-tetrafluoropropene (HFO1234yf). 
Postupak proizvodnje rashladnog sredstva prema zahtjevu 1, naznačen time, da obuhvaća miješanje 36 do 50 masenih postotaka 1,1,1,2-tetrafluoroetana (HFC134a) sa 50 do 64 masenih postotaka 2,3,3,3-tetrafluoropropana (HFO1234yf).
that it comprises a foldable or bendable portion; 
- sastoji se od složivog ili savitljivog dijela;
The resulting crude product is dried in a vacuum oven at 40 °C overnight to yield the titled product which is used crude in the next step. 
Dobiveni sirov proizvod se suši preko noći u vakuumskoj peći pri 40"C, čime se dobije naslovni proizvod koji se upotrebljava u slijedećem stupnju.
a door; and a door hinge mechanism, wherein; 
vrata (210); i mehanizam šarki za vrata kod kojeg:
—OR14; is hydrogen, substituted or unsubstituted C1-C4 linear alkyl, C6 or C10 substituted or unsubstituted aryl, C1-C9 substituted or unsubstituted heterocyclic, C1-C11 substituted or unsubstituted heteroaryl; 
R'* je vodik, supstituirani ili nesupstituirani C,-C, nerazgranati alkil, C, ili C,, supstituirani ili nesupstituirani aril, Ci-Co supstituirani ili nesupstituirani heterocikl, C;-C;, supstituirani ili nesupstituirani heteroaril;
a VL region as depicted in SEQ ID NO:71 or 75 and a VH region as depicted in SEQ ID NO:69 or 73; 
VL područje, kao što je opisano u SEQ ID NO:71 ili 75 i VH područje, kao što je opisano u SEQ ID NO:69 ili 73;
A pharmaceutical composition according to claim 1, further containing, a phosphate or citrate salt, sodium chloride, sodium edetate or a chelating agent. 
Farmaceutski pripravak prema patentnim zahtjevima 1-7, naznačen time da dalje sadrži, neovisno jedne od drugih, fosfatnu ili citratnu sol kao pufer, natrijev klorid kao sredstvo za toničnost, natrijev edetat kao konzervans i sredstvo za keliranje.
A process for preparing a compound as claimed in claim 1, the process comprising the following steps: reacting a compound of formula (II): 
Postupak dobivanja spoja u skladu s patentnim zahtjevom 1, naznačen time što se navedeni postupak sastoji u sljedećim koracima: reakcije spoja formule (II): t>&
The binding molecule capable of binding L1 for use of any of claims 5 to 13, wherein the chemotherapeutic drug is a DNA damaging agent, preferably selected from the group consisting of actinomycin-D, mitomycin C, cisplatin, doxorubicin, etoposide, verapamil, podophyllotoxin, 5-FU, taxans, preferably paclitaxel and carboplatin, or, wherein the radiotherapy is selected from the group consisting of X-ray radiation, UV-radiation, Y-irradiation, a- or B-irradiation, and microwaves. 
Vežuća molekula koja se može vezati na L1, namijenjena upotrebi u skladu s bilo kojim od patentnih zahtjeva 5 do 13, naznačena time što je kemoterapijski lijek sredstvo koje oštećuje DNA, koje se po mogućnosti bira iz skupine koju čine aktinomicin-D, mitomicin C, cisplatin, doksorubicin, etopozid, verapamil, podofilotoksin, 5-FU, taksani, po mogućnosti paklitaksel i karboplatin, ili, što se radioterapiju bira iz skupine koju čine rendgensko zračenje, UV-zračenje, Y-zračenje, a- ili B-zračenje, te mikrovalovi.
Pyridine (44 mmol) was added followed by drop wise addition of 3,3-dimethyl-butyryl chloride (44 mmol). 
Piridin (44 mmol) se doda, te potom polako dokapavajući 3,3-dimetil-butiril klorid (44 mmol).
The method of claim 9 wherein the lubricant is an alkali metal salt of a C8-C18 fatty acid. 
Postupak prema patentnom zahtjevu 9, naznačen time što je lubrikant so alkalnog metala C8-C18 masne kiseline.
If the initial volume of fluid from which IL-18BP is purified is large, it may be advantageous to reduce the volume of material by capturing the protein and resuspending it in a smaller volume of buffer before actually starting the purification process. 
Ukoliko je početni volumen tekućine iz koje se pročišćava IL-18BP veliki, može biti prikladno smanjiti volumen materijala na način da se ulovi protein te se resuspendira u manjem volumenu nekog pufera prije no se krene s procesom pročišćavanja.
Emergency service warning system, arranged to warn a user of approach of emergency services, provided with: 
Sustav za upozorenje koji je podešen tako da korisnika upozori na približavanje hitne službe, opremljen:
[125I]iodoamino-potentidine binding assay to the guinea pig H2 receptor. 
['"Iljodoamino-potentidin test za vezivanje na H2 receptor zamorca.
Ar1 represents a 5- or 6-membered heteroaryl selected from the group consisting of pyrrolyl, pyrazolyl, triazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiophenyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl; wherein said heteroaryl is unsubstituted or mono-substituted with (C1-4)alkyl; 
Ar1 predstavlja 5-člani ili 6-člani heteroaril odabran iz skupine koju čine: pirolil, pirazolil, triazolil, oksazolil, tiazolil, oksadiazolil, tiofenil, piridinil, pirimidinil, pirazinil, i piridazinil; dok je navedeni heteroaril nesupstituiran ili mono-supstituiran sa (C14)alkilom;
A method of preparing a compound of formula (I): or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof; 
LO Lo (6) OH ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese;
The pH of the loading material can be adjusted to a more acidic pH (such as pH 6.1) to adsorb less immunoglobulins and more r-hIL-18BP on the column during the loading step and remove as much as possible of the contaminating immunoglobulins. 
2000). pH materijala kojeg se nanosi na koloni može se podesiti na kiseliji pH HR P20080408 T3 (primjerice pH 6.1), kako bi se na kolonu u koraku nanošenja adsorbiralo manje imunoglobulina, a više r-hIL-18BP, i uklonilo što je više moguće kontaminirajućih imunoglobulina.
The sulphate salt of claim 1, having Formula II 
Sulfatna sol iz patentnog zahtjeva 1, koja ima formulu II ao
Subsequently, 55 g of piperidine was added over a period of 30 to 45 minutes, while maintaining the temperature at 0° to −5° C. The reaction mixture was maintained at 0° to 5° C. for 1.5 h. till completion of the reaction. 
Nakon toga, dodano je 55 g piperidina kroz razdoblje od 30 do 45 minuta, dok je temperatura održavana na 0 *C do -5" C. Reakcijska smjesa je održavana na 0-5 "C tijekom 1,5 sata do završetka reakcije.
Process of any one of the claims 1 to 4, wherein in the case of the conversion with reactant R1OH, wherein R1 is C1-6-alkyl the conversion with carbon monoxide is followed by a treatment with a hydrogen chloride producing agent. 
Postupak u skladu s bilo kojim od patentnih zahtjeva od 1 do 4, naznačen time, da u slučaju konverzije s reaktantom R'OH, pri čemu R' je C,x-alkil, nakon konverzije s ugljičnim monoksidom slijedi obrada u kojoj vodikov klorid proizvodi agens.
The thiol has a smell characteristic of compounds of its class, the intensity of the smell increasing with the concentration of the thiol. 
Tiol ima miris karakterističan za spojeve svoje klase, intenzitet mirisa se povećava s koncentracijom tiola.
An expression vector comprising the polynucleotide coding sequences of an antibody according to claim 1 or 2, 
Ekspresijski vektor, naznačen time što sadrži polinukleotidne sljedove koji kodiraju protutijelo u skladu s patentnim zahtjevom 1 ili 2.
wherein R1 is as defined for the compound of formula (3); first with a base and then with a compound of the formula CO2 to obtain the compound of formula (4), or salt thereof. 
R1 (1) gdje je RI vodikova ili dušikova zaštitna grupa; spomenuti postupak sadrži sljedeće korake (1) priprema spoja sa formulom (4), ili njegove soli,
Device according to claim 36, characterized in that the axis of rotation (63') of the rotary machining tool (63") is arranged such to extend essentially perpendicular to the surface to be processed. 
Uređaj u skladu s patentnim zahtjevom 30, naznačen time, stoje os rotacije (63) rotacijskog alata za obradu (63") postavljena tako da se pruža uglavnom okomito na površinu koja se treba obraditi.
wherein R1, PG, A-B are as defined above; and subjecting the compound of formula (3) to catalytic hydrogenation to remove the protecting groups PG and reduce the group A-B to an isopropyl group and thereafter, where the compound of formula (2) is prepared in the form of a free base, optionally converting the free base to an acid addition salt. 
PG-O naznačen time da su R', PG, A-B kako je definirano gore; i (b) podvrgavanje spoja formule (3) katalitičkoj hidrogenaciji radi uklanjanja zaštitnih skupina PG i, kada A-B označava C=CH,., reduciranja skupine A-B na izopropilnu skupinu i nakon toga, hdje se spoj formule (2) pripravlja u obliku slobodne baze, izborno pretvaranja slobodne baze u kiselinsku adicijsku sol.
is -H, halogen, perhaloalkyl, -CN, -OR5, -SR5, -NHR5, -N(R5)2, -OH, aryl, or heteroaryl, wherein said aryl can be optionally substituted with up to two substituents selected from C1-8alkyl, halogen, perhaloalkyl, and alkoxy, and said heteroaryl can be optionally substituted with up to two substituents selected from halogen and C1-8alkyl; 
je –H, halogen, perhaloalkil, -CN, -OR5, -SR5, -NHR5, -N(R5)2, -OH, aril ili heteroaril, pri čemu navedeni aril može po izbru biti supstituiran sve do sa po dva supstituenda izabrana iz skupine koju čine C1-8alkil, halogen, perhaloalkil i alkoksi te navedeni heteroaril može po izboru biti supstituiran sve do sa po dva supstituenda izabrana između halogena i C1-8akil;
A combination according to claim 8 wherein the active compound (c) is selected from the group consisting of (a) B2-agonists and (b) cortiocosteroids. 
Kombinacija sukladno patentnom zahtjevu 8, naznačena time, da je djelatni spoj (c) odabran iz skupine koja se sastoji od (a) inhibitora PDE IV 1 (b) kortiokosteroida.
The mouse of claim 1, wherein the mouse comprises: 12 to 40 unrearranged human immunoglobulin λ light chain variable region gene segments (hVλ) and at least one human Jλ (hJλ) gene segment; and a human Vk-Jk intergenic nucleic acid sequence located between the 12 to 40 human immunoglobulin light chain variable region gene segments and the at least one human Jλ nucleic acid sequence. 
HR P20160497 T1 najmanje jednog humanog JA (hJA) segmenta gena funkcionalno povezanih s mišjim Cx genom na mišjem lokusu endogenog lakog x lanca imunoglobulina, pri čemu se na spomenutom lokusu održava K element intronskog pojačivača uzlazno od Ck gena (označeno kao EKki) i 3'K pojačivač silazno od Cx gena (označeno kao EK3'); 1 humane VK-JK međugenske sekvencije nukleinske kiseline smještene između 12 do 40 humanih varijabilnih segmenata gena lakog imunoglobulinskog lanca i najmanje jedne JA sekvencije nuklemske kiseline; pri čemu miš izražava antitijelo koje sadrži laki lanac koji se sastoji od preuređene humane V2-J2.
—(C═O)m—NR10R11, wherein R10 and R11 are independently selected from the group consisting of: hydrogen, 
(10) -(C=0),,-NR"R'', gdje su R'" i R"" nezavisno izabrani iz grupe koju čine:
The necessary excess of autologous protein during the chemical conjugation, to guarantee its efficiency, is eliminated subsequently through the purification method of membrane ultrafiltration as previously described, that allows obtaining a vaccine composition with high homogeneity. The procedure described in the present invention to guarantee an appropriate chemical conjugation among both proteins consists of a single step and begins mixing the hrEGF protein previously concentrated (>6 mg/mL) and the protein rP64K (≧1 mg/mL) in the conjugation reactor. 
Postupak prema zahtjevu 9, naznačen time, da se konjugacijska reakcija sastoji od jednog koraka koji počinje miješanjem prethodno koncentriranih (>6 mg/mL) proteina hrEGF i (>1 mg/mL) proteina P64K u konjugacijskom reaktoru, onda nastavlja dodavanjem PBS/MgCI1, (pH 6,8-7,2) i konjugacijske otopine od 0,5% glutaraldehida u mješavinu, te se tada spomenuta mješavina inkubira na 22%C + 2%C s neprekidnim miješanjem u vremenu od dva sata.
The composition of claim 5 wherein the size distribution of the liposomes changes by no more than 15% after lyophilization and upon reconstitution of said liposomes. 
Sastav prema bilo kojem od zahtjeva 1-4, gdje raspored veličine liposoma se mijenja, ali ne više od 25% poslije liofilizacije i poslije rekonstrukcije spomenutih liposoma.
The composition of claim 5, wherein the mood stabilizer and/or antidepressant drug is selected from the group consisting of a fluoxetine, paroxetine, escitalopram, citalopram, sertraline, fluvoxamine, venlafaxine, milnacipram, duloxetine, mirtazapine, mianserin, reboxetine, bupropion, amitriptyline, nortriptiline, protriptyline, desipramine, trimipramine, amoxapine, s-citalopram, clomipramine, desipramine, doxepin, isocarboxazid, tranylcypromine, trazodone, nefazodone, phenelzine, lamatrogine, lithium, topiramate, gabapentin, carbamazepine, oxacarbazepine, valporate, maprotiline, mirtazapine, brofaromine, gepirone, moclobemide, isoniazid, and iproniazid. 
Pripravak za upotrebu prema zahtjevu 4, naznačen time da je stabilizator raspoloženja i/ili lijek protiv depresije odabran iz skupine koja sadrži fluoksetin, paroksetin, escitalopram, citalopram, sertralin, fluvoksamin, venlafaksin, milnacipram, duloksetin, mirtazapin, mianserin, reboksetin, bupropion, amitriptilin, nortriptilin, protriptilin, dezipramin, trimipramin, amokzapin, klomipramin, dezipramin, doksepin, izokarboksazid, tranilcipromin, trazodon, nefazodon, fenelzin, lamatrogin, litij, topiramat, gabapentin, karbamazepin, oksakarbazepin, valporat, maprotilin, mirtazapin, brofaromin, gepiron, moklobemid, izoniazid, i iproniazid.
The process of claim 9 wherein the activated cysteinamide residue is H-Cys(Npys)-NH2. 
Postupak prema patentnom zahtjevu 9, naznačen time, da aktivirani cisteinamidni ostatak jest H-Cys(Npys)-NH..
A pharmaceutical composition in the form of hydrophilic gel for transvaginal administration comprising a phosphodiesterase inhibitor, a polyhydroxy alcohol, water, a carbomer and an alkaline agent. 
Farmaceutski pripravak u obliku hidrofilnog gela za transvaginalnu primjenu sadrži inhibitor fosfodiesteraze, polihidroksilni alkohol, vodu, karbomer 1 alkalni agens, pri čemu je inhibitor fosfodiesteraze odabran iz skupine koja se sastoji od pentoksifillina, roliprama, milrinona i ibudilasta.
a closed reactor (1) provided with an inlet and an outlet for said waste water, and with thermostat control means (2), and means (3) for inducing a recirculating flow arranged for fluidizing a granular material contained inside said reactor, wherein said granular material is arranged for serving as an inert supporting medium for an adherent bacterial flora that implements process of fluidized-bed thermophilic aerobic biological treatment; 
- < zatvoreni reaktor (1) s ulazom 1 izlazom za tu otpadnu vodu, i s termostatskom kontrolom (2), i sredstvima (3) za induciranje recirkulacijskog protoka postavljenog za fluidizaciju granularnog materijala koji se nalazi u tom reaktoru, pri čemu je taj granularni materijal postavljen da posluži kao inertni potporni medij za prijanjajuću bakterijsku floru koja provodi postupak termofilne aerobne biološke obrade u fluidiziranom sloju;
a neck part at the outlet end; 
- - watni dio na izlaznom kraju;
When the plate 21 is housed within the interspace 22, the filter 13a is aligned with a conduit 24 central to the filter changer 7a, and through which the molten mixture can pass. 
Kada se ploča 21 nalazi u međuprostoru 22, filtar 13a se poravna s cijevi 24 tako da se centrira u odnosu na filtarski izmjenjivač 7a i kroz njega može prolaziti rastopljena mješavina.
In addition to this, in step (a) elution was carried out using 0.06 M ammonium acetate at pH 8.7. 
Nadalje, u koraku (a) elucija je provedena s 0.06 M amonijevim acetatom kod pH 8.7.
a protective layer and a waterproofing layer for the outer face 18 of said hollow structure 16, described in more detail further on, 
- zaštitni sloj (14) i vodootporni sloj (15) za vanjski dio (18) navedene šuplje strukture (16),
in which Z has the meanings indicated in claim 1, with a compound of formula Ill in which R1, R2 and R3 have the meanings indicated in claim 1, and L denotes Cl, Br, I or a free or reactively functionally modified OH group, 
L R3 sa spojem s formulom III u kojoj R!, R* i R* imaju značenja navedena u zahtjevu 1, i L označava CI, Br, Lili slobodnu ili reaktivno funkcionalno modificiranu OH skupinu, i/ili baza ili kiselina s formulom I se pretvara u jednu od njihovih soli.
A process for preparing a spontaneously dispersible pharmaceutical composition, wherein the spontaneous dispersible pharmaceutical composition is a microemulsion preconcentrate, containing about 0.05 to about 20% by weight of 7-t-butoxyiminomethylcamptothecin as an active agent, which process comprises bringing the active agent and a carrier medium comprising about 5 to about 85% by weight of a lipophilic component, 
Postupak priprave spontano disperzibilnog farmaceutskog pripravka u skladu s patentnim zahtjevom 1, naznačen time što se navedeni postupak sastoji u dovođenju aktivnog sredstva i nosivog medija koji sadrži (1) navedenu lipofilnu komponentu, (2) navedeni surfaktant, (3) navedenu hidrofilnu komponentu u intimnu smjesu, uz (4) izborno suotapalo.
in response to a fired shot, the passing of first the second magnetic pole and subsequently the first magnetic pole at the coil, so that thereby opposite voltages are induced at the coil; 
prolaženje, najprije drugog magnetskog pola (3a, 8a) i zatim prvog magnetskog pola (2b, 8b) mimo zavojnice (1), kao reakcije na ispaljeni hitac, tako da se u zavojnici (1) induciraju suprotni naponi;
a first folding means for folding a napkin along a first fold; adhesive applying means operable to apply first and second adhesive portions onto a first surface of said napkin; and a second folding means for folding said napkin along a second fold such that said first and said second adhesive portions are brought into engagement with each other; 
preklapanja ubrusa duž prvog nabora; nanošenja prvog i drugog prijanjajućeg dijela (102, 104) na prvu površinu (106) ubrusa; i preklapanje navedenog ubrusa duž drugog nabora tako da navedeni prvi i drugi prijanjajući dijelovi međusobno naliježu; pri čemu je navedeni adheziv takve vrste koja će omogućiti navedenim prvim i drugim prianjajućim dijelovima razdvajanje i omogućiti navedenom ubrusu prianjanje na objekt.
the method further comprises adapting the monitoring of the property of the coating of the solid dosage form in accordance with a characteristic of the coating process forming the coating. 
postupak nadalje uključuje prilagođavanje praćenja svojstva prevlake čvrstog oblika doziranja u skladu s karakteristikama postupka prevlačenja koji nanosi prevlaku.
The installation according to claim 1, wherein the installation forms part of the deluge fire extinguishing system or is permanently installed thereon, therein or in fluid connection therewith. A method for testing a deluge fire extinguishing system, comprising the following steps to be performed in any suitable order: 
Instalacija (1) sukladno bilo kojem od prethodnih zahtjeva, pri čemu instalacija (1) formira dio otvorenog, deluge (gašenje vodom i/ili pjenom) sustava za gašenje požara ili je trajno instalirana na isti, u isti ili u fluidnoj povezanosti s istim.
The protein-binding segment of a DNA-targeting RNA of the present disclosure comprises two stretches of nucleotides (a targeter-RNA and an activator-RNA) that are complementary to one another, are covalently linked by intervening nucleotides (e.g., in the case of a single-molecule DNA-targeting RNA)(“linkers” or “linker nucleotides”), and hybridize to form the double stranded RNA duplex (dsRNA duplex, or “dCas9-binding hairpin”) of the protein-binding segment, thus resulting in a stem-loop structure. 
(ii) segment koji veže protein 1 koji međudjeluje s kimernim proteinom Cas9, pri čemu segment koji veže protein, obuhvaća dva komplementarna odsjeka nukleotida koji hibridiziranju za tvorbu dvostruke RNK strukture (AsRNK)-dupleks, te time, da su (a) i (b) u zajedničkom spremniku ili u odvojenim spremnicima.
A pharmaceutical composition comprising a compound as defined in any of embs. 
Farmaceutska smjesa koja sadrži spoj kako je definiran u zahtjevu 1.
Naphthalene-derived compounds characterized by the structure I, In structure I, the terms are designated as R: 
Spojevi derivirani iz naftalena, naznačeni strukturom I, [image] U strukturi I, izrazi označeni kao R su:
The antibody for use according to any one of claims 1 to 6, wherein the antibody is an IL-11 binding antibody. 
Protutijelo za uporabu u postupku liječenja ili prevencije fibroze prema zahtjevu 1 ili zahtjevu 2, naznačeno time, da se kod protutijela radi o protutijelu koje se veže na IL-11.
After completion of the administration period, the thoracic aorta was isolated and stained to determine the area of the atherosclerotic injuries deposited in the internal wall of the blood vessel in according with the Red Oil method (Lillie, R.D., 1994, Stain Technology, vol. 
Po završetku perioda davanja, izolirana je prsna aorta i obojena da se utvrdi površinu ateroskleroznih ozljeda nastalih na unutarnjoj stijenci krvne žile u skladu s metodom Red Oil (Lillie, R.D., 1994, Stain Technology, sv.